Spots Global Cancer Trial Database for CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Official Title: Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas
Study ID: NCT00017446
Conditions
Interventions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CP4071 in treating patients who have locally advanced or metastatic soft tissue sarcoma.
Detailed Description: OBJECTIVES: * Determine the efficacy, in terms of response rate, of CP4071 in patients with previously treated, locally advanced or metastatic soft tissue sarcoma. * Determine the clinical toxic effects of this drug in these patients. OUTLINE: Patients receive oral CP4071 daily. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Contact Details
Name: Robert N. Taub, MD, PhD
Affiliation: Herbert Irving Comprehensive Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
